| Property | Value |
|---|
|
?:abstract
|
-
Therapeutic drug monitoring (TDM) of hydroxychloroquine has been recommended to optimize the treatment of COVID-19 patients. The authors describe an ultra-high-performance liquid chromatography tandem spectrometry ( UHPLC-MS/MS) method developed in a context of emergency, to analyze hydroxychloroquine (HCQ) in both human plasma and blood samples.After adding the labeled internal standard and simple protein precipitation, plasma samples were analyzed using a C18 column. Blood samples required evaporation before analysis. The total chromatographic run time was 4 min (including 1.5 min of column equilibration). The assay was linear over the calibration range (r > 0.99) and up to 1.50 µg/mL for the plasma samples (5.00 µg/ml for the blood matrix). The limit of quantification was 0.0150 µg/mL for plasma samples (0.05 µg/ml blood matrix) with accuracy and precision ranging from 91.1 % to 112 % and from 0.750 % to 11.1 %, respectively. Intra- and inter-day precision and accuracy values were within 15.0 %. No significant matrix effect was observed in the plasma or blood samples. This method was successfully applied to patients treated for COVID-19 infection. A simple and rapid UHPLC-MS/MS method adapted to HCQ TDM in the context of SARS-CoV-2 infection was successfully developed and validated.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}